Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthelabo, dated March 19, 2004, reports on the financing activities related to its public offer to acquire Aventis. The document serves as a notification of the successful completion of the first round of syndication for a credit facility established to fund this transaction.
Key Financial Metrics
The filing does not provide standard operating financial metrics such as revenue, profit, cash flow, margins, or existing debt levels. The primary financial data point disclosed is the establishment of a 12 billion euro credit facility to finance the acquisition of Aventis.
Material Changes
The material change reported is the successful syndication of the 12 billion euro credit facility. The international syndicate now includes the following banks alongside Mandated Lead Arrangers BNP Paribas and Merrill Lynch:
- ABN AMRO Bank
- Banco Bilbao Vizcaya Argentaria
- The Bank of Tokyo-Mitsubishi
- CDC Finance - CDC IXIS
- Natexis Banques Populaires
- The Royal Bank of Scotland
- WestLB AG
Outlook, Risks, and Contingencies
Management indicates that the financing for the Aventis offer is proceeding as planned. The filing highlights several contingencies and regulatory requirements:
- Regulatory Filings: Sanofi-Synthelabo has filed a registration statement on Form F-4 (File no. 333-112314) with the SEC and will file additional documents.
- Investor Warning: Investors are urged to read the registration statement and related documents for important information regarding the transaction.
- German Offer: A specific offer prospectus issued under German law on March 11, 2004, applies exclusively to holders of Aventis ordinary shares located in Germany.
- French Prospectus: The offer prospectus in France has been granted visa number 04-0090 by the Autorite des marches financiers (AMF).
Key Facts for Investor Verification
- Verify the terms and conditions of the 12 billion euro credit facility in the information notice registered with the AMF (number 04-0090).
- Review the Form F-4 registration statement (File no. 333-112314) filed with the SEC for details on the acquisition structure.
- Confirm the specific terms applicable to German shareholders via the German offer prospectus issued on March 11, 2004.
- Note that the filing text does not provide clear values for Sanofi-Synthelabo's current liquidity, debt ratios, or operating results.